This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street

Core Viewpoint - Exact Sciences has seen a significant decline in stock performance, down 41% this year, despite some analysts projecting a potential upside of 93% based on an average price target of $83.46 [1][2] Company Overview - Exact Sciences specializes in developing innovative cancer diagnostic tests, with its flagship product being Cologuard, a non-invasive colorectal cancer screening test [2] - The company reported revenue of$638 million in the first quarter, reflecting a year-over-year growth of just under 6% [2] Financial Performance - Exact Sciences remains unprofitable, with a net loss per share of $0.60, which is worse than the$0.42 loss reported in the same period last year [3] - The company's marketing and advertising expenses have decreased as a percentage of revenue, from 114% in 2016 to 29.1% last year, which is expected to positively impact margins and the bottom line [6] Competitive Landscape - Exact Sciences faces increasing competition, particularly from Guardant Health, which is nearing FDA approval for its colorectal blood cancer test, potentially impacting Cologuard's market share [3] Future Prospects - The company is working on a next-generation Cologuard that has shown a 30% decrease in false positives in late-stage studies, with expectations for approval next year [4] - There are approximately 60 million eligible patients who are not adhering to recommended screening schedules, indicating a significant market opportunity for Cologuard [4] - Exact Sciences is also developing other products, including multi-cancer screening options, which could be lucrative if approved [6] Marketing Strategy - The company is increasing awareness through aggressive marketing campaigns, which is crucial for addressing the screening gap in colorectal cancer [5]